Abstract
We read the two articles published in a recent issue of Diabetes Care by Lewis et al. (1) and Ferrara et al. (2) with interest. The first study tested a time-dependent use of pioglitazone for the risk of bladder cancer among 193,099 diabetic patients in the Kaiser Permanente Northern California Diabetes Registry and concluded that use of the drug over 24 months was associated with an increased risk of bladder cancer (hazard ratio 1.4, 95% CI 1.03–2.0). The second study tested a time-dependent use of pioglitazone for the risk of cancer among 252,467 diabetic patients aged ≥40 years from the Kaiser Permanente Northern California Diabetes Registry and found that ever use of pioglitazone was not …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.